Endo Health Solutions' quarterly profit of anesthetic and generic drugs beat analysts' expectations with a 29 percent — or $785 million — revenue increase, according to Reuters.
Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
Tony Mira: Analyzing Anesthesiologists’ Investments in ASCs
Mylan's Generic Anesthesia Drug Approved by FDA
Mission Hospital Renews Partnership With Asheville Anesthesia Associates
Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
Tony Mira: Analyzing Anesthesiologists’ Investments in ASCs
Mylan's Generic Anesthesia Drug Approved by FDA
Mission Hospital Renews Partnership With Asheville Anesthesia Associates